IL-1 Genotype Stratification for Recurrent Cardiovascular Event Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular disease (CVD) with statins are ineffective in preventing recurrent CVD events in 20-30% of patients, despite lowering LDL-C levels, and there is a need to identify individuals susceptible to recurrent events for enhanced monitoring and therapeutic interventions.
Innovation Solution
The discovery of specific IL-1 genotype patterns that stratify individuals into groups based on their likelihood of over-producing IL-1 and responding to clinical indicators such as Lp(a), OxPL, triglyceride-rich lipoprotein, LDL-C, CRP, and hypertension, enabling prediction of recurrent cardiac events and personalized treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If statins are used to lower LDL-C levels, then cholesterol levels are reduced, but recurrent CVD events still occur in 20-30% of patients
Solution Approach 1:
The patent applies parameter changes by shifting from monitoring only LDL-C levels to evaluating multiple parameters including Lp(a), CRP, and IL-1 genotype patterns. This multi-parameter approach identifies patients at high risk for recurrent events despite adequate LDL-C control, enabling more reliable prevention strategies through personalized risk assessment and targeted therapeutic interventions.
2Quantity of substance
If standard pharmacological treatment is provided, then LDL-C levels are lowered, but prediction of recurrent CVD events remains insufficient
Solution Approach 1:
The patent applies segmentation by dividing patients into distinct risk groups based on IL-1 genotype patterns (risk alleles vs. non-risk alleles). This segmentation allows for personalized prediction of recurrent CVD events, where patients with risk alleles and elevated Lp(a) or CRP levels are identified as high-risk, enabling more precise measurement and prediction of event probability rather than using uniform treatment protocols.
3Reliability
If increased monitoring and aggressive treatment are provided to all patients, then recurrent events may be prevented, but treatment complexity and cost increase
Solution Approach 1:
The patent applies local quality by tailoring treatment intensity to specific patient subgroups rather than applying uniform aggressive treatment to all patients. Patients with IL-1 risk alleles, elevated Lp(a), and high CRP levels receive intensified monitoring and aggressive lipid-lowering therapy, while other patients receive standard care. This localized approach maintains high reliability for prevention in high-risk groups without unnecessarily increasing complexity for low-risk patients.
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
The present invention relates to methods and kits for treating cardiovascular disease.